Relationship between spectral analysis, SUV and SUV Pons ratio as a measure of cerebral glucose metabolic rate in Alzheimer's disease : Neuroimaging / multi‐modal comparisons

Medientyp: E-Artikel
Titel: Relationship between spectral analysis, SUV and SUV Pons ratio as a measure of cerebral glucose metabolic rate in Alzheimer's disease : Neuroimaging / multi‐modal comparisons : Neuroimaging / multi‐modal comparisons
Beteiligte: Edison, Paul; Raza, Sanara; Femminella, Grazia Daniela; Blunt, Eleanor G; Carver, Stefan; Livingston, Nicholas R; Nowell, Joseph; Holmes, Clive; Ritchie, Craig W.; Lawrence, Robert M; McFarlane, Brady; Tadros, George; Ridha, Basil H; Bannister, Carol; Walker, Zuzana; Archer, Hilary; Coulthard, Elizabeth; Underwood, Ben; Prasanna, Aparna; Koranteng, Paul; Karim, Salman; Junaid, Kehinde; McGuinness, Bernadette; Nilforooshan, Ramin; [...]
Erschienen: Wiley, 2020
Erschienen in: Alzheimer's & Dementia
Sprache: Englisch
DOI: 10.1002/alz.046068
ISSN: 1552-5260; 1552-5279
Schlagwörter: Psychiatry and Mental health ; Cellular and Molecular Neuroscience ; Geriatrics and Gerontology ; Neurology (clinical) ; Developmental Neuroscience ; Health Policy ; Epidemiology
Entstehung:
Anmerkungen:
Beschreibung: <jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Cerebral metabolic rate of glucose (CMRglc) can be measured with fluorodeoxyglucose (FDG) positron emission tomography (PET) using arterial blood sampling. However, blood sampling is an invasive methodology for subjects. Standard uptake value (SUV) is a non‐invasive method to assess the cerebral glucose metabolism. Here we evaluate the relationship between semi‐quantitative measurements such as SUV and Pons ratio with a quantitative measurement such as Spectral analysis (SA) in order to assess their surrogate use in clinical trials.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>To assess cerebral glucose metabolism by a non‐invasive and simplified method, the standardized uptake value (SUV) and used the Pons RATIO (where target region was divided by pons as a reference region, which requires no arterial input function or blood sampling. The SA was performed using blood sampling to create the input function. The study participants included 63 subjects (mean ± SD age, 71 ± 8 years) from the Evaluating Liraglutide in Alzheimer’s Disease (ELAD) trial. Regional CMRglucose (CMRglc) and regional SUV were measured using FDG PET, and the correlation between CMRglc and SUV together with CMRglc and Pons ratio were estimated for the temporal lobe, medial temporal lobe and hippocampus</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>In this AD population, the SA and SUV in the temporal lobe (r=0.635, p= >0.001), medial temporal lobe (0.533, p= >0.001) and hippocampus (r=0.539, p= >0.001) had a positive correlation and were statistically significant. The correlation coefficient between SA and Pons ratio for the temporal lobe (r=0.166, p= 0.194), medial temporal lobe (r=0.146, p=0.146) and the hippocampus (r=0.193, p=0.129) was positive but not statistically significant.</jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p>The SUV correlated better with cerebral glucose metabolic rate using SA than Pons RATIO in AD subjects, while Pons RATIO did not perform well. Therefore, SUV analysis maybe more reliable analysis method compared to Pons RATIO for FDG PET in clinical trials in AD subjects.</jats:p></jats:sec>

Nur in Feld suchen:

Zuletzt gesuchte Begriffe: